Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children
1
Department of Medicine, College of Medicine, Yeungnam University, Daegu 42415, Korea
2
Department of Pediatrics, College of Medicine, Yeungnam University, Daegu 42415, Korea
*
Author to whom correspondence should be addressed.
†
So Rae Lee, Su Min Kim, and Min Young Oh contributed equally to this study.
Children 2020, 7(9), 140; https://doi.org/10.3390/children7090140
Received: 21 August 2020
/
Revised: 11 September 2020
/
Accepted: 15 September 2020
/
Published: 16 September 2020
(This article belongs to the Section Oncology and Hematology)
This study was conducted to investigate the safety and efficacy of olanzapine for high and moderate emetogenic chemotherapy in children and young adults. We retrospectively reviewed the records of pediatric patients (n = 13) with cancer who had been administered olanzapine as an anti-emetic drug (AED) during a high and moderate emetogenic chemotherapy block from January 2018 to March 2020. Patients were administered other prophylactic AEDs according to practice guidelines. The mean age of the patients was 14.1 ± 5.5 years. The total number of chemotherapy cycles was 41. Twenty-one (51.2%) chemotherapy blocks were high emetogenic chemotherapy and 20 (48.8%) blocks were moderate emetogenic chemotherapy. Olanzapine was used for prophylaxis in 20 (48.8%) blocks of chemotherapy and rescue in 21 (51.2%). Of the 41 cycles, a complete response to olanzapine was achieved in 31 (75.6%), partial response in 6 (14.6%), and no response in 4 (9.8%). The mean dose was 0.07 ± 0.04 mg/kg/dose and 2.50 ± 1.37 mg/m2/dose. Adverse effects included somnolence, hyperglycemia, fatigue, and disturbed sleep. Our findings indicate that olanzapine was effective and safe for treating chemotherapy-induced nausea and vomiting in children. A prospective controlled study is needed to confirm these findings.
View Full-Text
Keywords:
adolescent; antiemetics; childhood cancer; chemotherapy-induced nausea and vomiting; olanzapine
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Lee, S.R.; Kim, S.M.; Oh, M.Y.; Lee, J.M. Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children. Children 2020, 7, 140. https://doi.org/10.3390/children7090140
AMA Style
Lee SR, Kim SM, Oh MY, Lee JM. Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children. Children. 2020; 7(9):140. https://doi.org/10.3390/children7090140
Chicago/Turabian StyleLee, So R., Su M. Kim, Min Y. Oh, and Jae M. Lee. 2020. "Efficacy of Olanzapine for High and Moderate Emetogenic Chemotherapy in Children" Children 7, no. 9: 140. https://doi.org/10.3390/children7090140
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
